Initial Treatment and Cost of Care in Pulmonary Hypertension

Slideshow

A new study finds that the first treatment chosen to treat PAH may help mitigate the burden of all-cause cost of care.

Treatment options for PAH are evloving, yet patient prognosis remains poor. PAH also confers a heavy ecomomic burden related to cost of drugs, hospitalizations, and comorobidities. There is research that suggests initial treatment with PAH-specific medications (vs combinations of agents) may decrease healthcare utilization. Could this strategy tranlsate into reduced overall healthcare costs to treat PAH? 

Recent Videos
Deepak Bhatt, MD, MPH, MBA | Credit: Mount Sinai Heart
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Siddharth Patel, MD, MPH | Credit: TIMI Study Group
Kausik Ray, MD, MPhil | Credit: BAIM Institute
Rahul Aggarwal, MD | Credit: LinkedIn
Kenneth Mahaffey, MD | Credit: Stanford University
Sara Diaz Saravia, MD | Credit: X.com
Deepak Bhatt, MD, MPH, MBA | Credit: Mount Sinai Heart
© 2024 MJH Life Sciences

All rights reserved.